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Abstract
Transforming growth factor-b (TGF-b) signaling is tightly regulated at the level of post-translational modification to
transmit quantitative difference in ligand concentration into proportional transcriptional output. Ubiquitination is
one such modification with several E3 ubiquitin ligases implicated in TGF-b signaling in marking crucial pathway
components for proteasomal degradation. However, ubiquitination, particularly in the mono- or oligo-ubiquitin
modifying form, is also known to regulate incorporation of substrate proteins into signaling complexes that
involved in DNA repair, kinase activation, and endocytosis. This review focuses on recent advances in
understanding the role of such non-degradative ubiquitination in TGF-b signaling.
Introduction
The transforming growth factor-b (TGF-b)s u p e r f a m i l y
consists of more than 30 secreted polypeptide growth
factors including, but not limited to, TGF-bs, bone mor-
phogenetic proteins (BMPs), activin/inhibin, growth and
differentiation factors (GDFs) and nodal [1-3]. These
cytokines regulate a wide array of biological processes
ranging from cell proliferation and differentiation to
migration and apoptosis [2,4]. Binding of ligands to the
type II receptor (TbRII) recruits the type I receptor
(TbRI), both of which are serine/threonine kinases,
resulting in the formation of a heterotetrameric receptor
complex. Within this complex, TbRI is activated by
TbRII through phosphorylation, and the activated TbRI
phosphorylates receptor-regulated Smad2 and Smad3
(R-Smads) at two serine residues in the C-terminus
[2,5]. The C-terminal phosphorylation enables R-Smads
to form heteromeric complexes with Smad4, which is
commonly required for signaling by different R-Smads.
The Smad complexes then accumulate in the nucleus to
regulate target gene expression cooperatively with other
transcription factors in a cell context-dependent manner
[2,4,6]. A third class of Smads, mainly consisting of
Smad6 and Smad7, negatively regulate TGF-b and BMP
signaling by competing with R-Smads for binding to
TbRI or targeting receptors to proteasomal degradation,
therefore are named the inhibitory Smads (I-Smads)
[7-10]. In addition to this canonical Smad-dependent
signaling, TGF-b and its related ligands are also capable
of activating small GTPases, mitogen-activated protein
kinases, and phosphatidylinositol-3-kinase, initiating the
so-called Smad-independent, noncanonical pathways
[11].
Ubiquitin modification occurs in a three-step enzy-
matic reaction, which is catalyzed sequentially by ubi-
quitin activating enzyme (E1), ubiquitin conjugase (E2),
and ubiquitin ligase (E3), resulting in attachment of ubi-
quitin to lysine residues of target proteins. Among these
enzymes, the E3 ubiquitin ligase plays a crucial role in
substrate recognition. Mammalian genomes contain
more than 600 E3 ligases, which are divided into two
categories based on sequence homology of the E2-bind-
ing domain: the Homologous to E6-AP Carboxyl Termi-
nus (HECT) domain-containing E3s, and the Really
Interesting New Gene (RING) finger domain-containing
E3s [12]. Like phosphorylation, which can be reversed
by the action of phosphatases, ubiquitination is also
reversible by deubiquitination enzymes (DUBs) that
cleave off ubiquitin moieties from substrates [13,14].
Different types of ubiquitin modifications are classified
according to the number of ubiquitin moieties attached
to substrates and the choice of lysine residue for the
ubiquitin chain linkage. Poly-ubiquitination via the K48
linkage generally targets substrates for degradation by
the 26S proteasome and regulates essentially all aspects
of cellular functions[15], whereas mono- and oligo-ubi-
quitination or poly-ubiquitination via the K63 linkage
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kinase activation, and endocytosis [16]. Initially, various
TGF-b pathway components were thought to be modi-
fied strictly by poly-ubiquitination and proteasome-
mediated degradation that attenuates signaling output
[17,18]; however, subsequent experiments demonstrate
that some pathway components receive non-degradative
ubiquitin modification in the form of mono-, oligo-, or
even poly-ubiquitination that can lead to pathway acti-
vation under certain conditions[19,20]. The impact of
degradative ubiquitination by different E3 ligases has
been thoroughly summarized [17,18], so this review will
focus on discussing recent advances in non-degradative
ubiquitination in TGF-b signaling.
Multiple mono-ubiquitination of Smad3 inhibits TGF-b-
mediated transcriptional responses
Two recent studies have revealed that Smad3 undergoes
multiple mono-ubiquitination, but this type of modifica-
tion exerts no impact on Smad3 stability and phosphor-
ylation. Instead, mono-ubiquitination of Smad3
modulates its transcriptional activity. Work from Ste-
fano Piccolo’s group identified multiple lysines of Smad3
including K33, K53, and K81 as recipients of mono-ubi-
quitin modification in HEK293T cells [21] (Figure 1).
Ubiquitination at these residues affects DNA-binding
activity of Smad3 since only unmodified Smad3 was
pulled down by oligonucleotide probes containing the
Smad-binding element [21]. Interestingly, mono-ubiqui-
tination only inhibits direct interaction between Smad3
and DNA mediated by the Smad3 DNA-binding
domain, but has no effect on indirect binding of Smad3
to DNA via other transcriptional factors. Formation of
the Smad transcription complex favors Smad3 mono-
ubiquitination, as this ubiquitination was shown to be
enhanced by TGF-b but was inhibited in Smad4-
depleted cells or in cells treated with the transcriptional
inhibitors. On the other hand, ubiquitination of Smad3
causes it to be dissociated from DNA, because incubat-
ing Smad3 with either Smurf2 or NEDD4L, two pre-
viously characterized HECT E3 ligases in TGF-b
signaling, released Smad3 in the ubiquitinated forms.
Their work further showed that mono-ubiquitination of
Smad3 can be reversed by de-ubiquitin enzyme, USP15,
and knockdown of USP15 abolishes the recruitment of
TGF-b-activated Smad complex on the chromatin (Fig-
ure 2). Thus, mono-ubiquitination can act in a self-lim-
iting step during pathway activation and removal of
ubiquitin modification by USP15 empowers Smad3 in
the transcription response that it induces.
Concurrent to Piccolo’ss t u d y ,o u rg r o u pm a d ea n
independent observation of Smad3 mono-ubiquitination
in mouse embryonic fibroblasts (MEFs), and demon-
strated that Smurf2 is the catalyzing enzyme[22].
Although both Smurf1 and Smurf2 were initially identi-
fied as E3 ligases that modulate TGF-b and BMP signal-
ing, subsequent studies expanded the repertoire of their
substrates to many other signaling pathways, and even
in the process of epithelial to mesenchymal transition
where TGF-b signaling is intimately involved, Smurf1
was found in a complex with Par6 to promote the loca-
lized degradation of RhoA at cell junction rather than
acting through controlling the levels of Smads or TbRI
[23]. These experimental observations raised the doubt
on the physiological relevance of Smurfs in TGF-b/BMP
signaling. Indeed, experiments with luciferase reporters
monitoring transcriptional responses or Western blot
analyzing Smad phosphorylation levels showed that loss
of Smurf1 had little effect on TGF-b signaling [24], and
data from Smurf1 and Smurf2 double knockout mice
indicated that these two E3 ligases share a common
function in regulating planar cell polarity by regulating
asymmetric distribution of Prickl1 of the non-canonical
Figure 1 Schematic diagram of ubiquitination sites in Smad3
and Smad4. The conserved MH1 domain and MH2 domain are
shown in blue and red, respectively. The non-conserved regions
including the linker are shown in white. PY-motif, which is
important for Smurf2 binding and ubiquitination, is shown in green.
Figure 2 A model for mono-ubiquitination in TGF-b signaling.
Upon TGF-b stimulation, Smad3 is phosphorylated at sites in both
the linker and the C-terminal tail. Phosphorylation of T179 in the
linker region potentiates Smurf2 binding and the subsequent
mono-ubiquitination. Smad3 mono-ubiquitination can be reversed
by USP15. On the other hand, mono-ubiquitination of Smad4 is
induced by Ecto/Tif1g, and reversed by FAM/USP9x. The unmodified
Smad3 and Smad4 form a DNA binding complex that regulates
target gene expression whereas mono-ubiquitinated Smad3 or
Smad4 inhibits or disrupts the Smad complex formation.
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if indeed Smurf2 plays any role in TGF-b signaling and
to address its physiological function, we generated
Smurf2-deficient mice[22]. This allowed a rigorous loss-
of-function examination of any possible role of this E3
ligase during embryogenesis and with biochemical analy-
sis and reporter assays in isolated MEFs under in vivo
conditions. By carefully examining the levels of various
pathway components and transcriptional readouts in
MEFs isolated from wild type, Smurf2
-/-,a n dSmurf1
-/-
mice, we found that Smurf2 is a specific E3 ligase
responsible for multiple mono-ubiquitination of Smad3
[22]. Interestingly, the level of ubiquitin modified Smad2
is not affected in Smurf2
-/- MEFs, even though Smad2
shares 92% sequence identity with Smad3, implying a
high degree of substrate selectivity of Smurf2-mediated
mono-ubiquitination reaction. Similar to the poly-ubi-
quitin modification of Smad3 induced by NEDD4L [26],
interaction between Smurf2 and Smad3 as well as
Smurf2-induced mono-ubiquitination of Smad3 requires
phosphorylation of T179 and the adjacent PY motif
(PPGY) in the linker region[22]. This requirement
affords additional regulation of Smad3 activity to TGF-
b, which has been shown to signal through cyclin-
dependent kinases to control phosphorylation of T179
[27,28]. The sites of ubiquitination were mapped to four
lysine residues in the MH2 domain, namely K333, K341,
K378, and K409 [22](Figure 1). Since these lysines lie in
the MH2 domain is positioned at the intermolecular
interface of Smad3 complexes, it is conceivable that ubi-
quitination of these sites would inhibit formation of
either the homomeric Smad3 or the heteromeric
Smad3/Smad4 complexes [29]. This notion has been
supported by evidence obtained with both in vivo co-
immunoprecipitation experiments and in vitro GST
pull-down assays[22]. Furthermore, we found that
Smad3 accumulated more in the nucleus, and the rate
of Smad3 export from the nucleus to the cytoplasm also
decreased significantly in Smurf2
-/- MEFs upon TGF-b
treatment, which offers a reasonable explanation for the
elevated Smad3-dependent TGF-b transcriptional
response that was observed in Smurf2
-/- MEFs[22].
Thus, upon TGF-b ligand binding to the receptors,
phosphorylation of Smad3 at T179 in the linker region
renders it a suitable substrate for Smurf2-mediated
mono-ubiquitination (Figure 2). This modification inter-
feres with Smad3 complex formation due to steric hin-
drance at the inter-molecular interface involving the
MH2 domain, constituting a previously unnoticed nega-
tive feedback regulatory loop. These data unequivocally
demonstrated a role of Smurf2 in modulating TGF-b
signaling under in vivo conditions, albeit with a minimal
role during embryogenesis. Further experimentation is
required to identify the right environmental signals that
invoke such fine tuning mechanism and, for that matter,
its physiological significance.
Itch mediated poly-ubiquitination enhances Smad2
phosphorylation by TbRI
Another HECT-domain E3 ligase, Itch, which shares
structural similarity with Smurfs has been implicated in
controlling TGF-b signaling. Loss of Itch leads to
reduced responses to TGF-b signaling in fibroblasts, but
in analogous to the situation in Smurf2
-/- cells, the levels
of several Smads were found to be relatively constant in
Itch
-/- MEFs comparing to those in Itch
-/+ control cells
[19]. Itch can form a tripartite complex with Smad2 and
the activated TbRI. Poly-ubiquitination of Smad2 by
Itch in this complex was shown to enhance interaction
between Smad2 and TbRI, thereby promoting phosphor-
ylation of Smad2. Thus, unlike Smurfs, Itch exerts a
positive influence on TGF-b signaling [19]. The signifi-
cance of this work is that it demonstrates that Itch posi-
tively regulates TGF-b signaling by enhancing TbRI
induced-Smad2 phosphorylation in an ubiquitination-
dependent manner. However, the underlying mechanism
that controls interaction between Itch and Smad2, and
how ubiquitination facilitates Smad2-TbRI interaction
are not clear.
Poly- and oligo-ubiquitin modifications of Smad4
differentially regulate its activity
Smad4 was initially identified as a frequent deletion tar-
get in pancreatic carcinomas, and Smad4 deletions or
mutations were also found in colon, breast, and lung
cancers, albeit with less frequency [30]. Consistent with
these findings, studies of mice carrying various targeted
mutations indicated that loss of Smad4 results in tumor
formation in multiple organs and tissues[31-33]. In can-
cer cells, a panel of 4 missense mutations in the MH1
domain of Smad4 identified in human pancreatic and
colorectal cancers was reported to render the mutant
Smad4 a better substrate for poly-ubiquitin modification
and proteasome-mediated degradation [20]. However, in
normal cells wild type Smad4 is actually a quite stable
protein, as it is a poor substrate of poly-ubiquitination
and turns-over very slowly even in the presence of
cycloheximide [20]. Instead, wild type Smad4 is sub-
jected to mono- and oligo-ubiquitin modification in the
MH2 domain. However, the literature differs signifi-
cantly with regard to the impact of mono- and oligo-
ubiquitin modification on Smad4 function with one
report from Moustakas’ group suggesting that it
enhances formation and transcriptional activity of the
Smad3-Smad4 complex [20] whereas another from Pic-
colo’s concluding in quite an opposite direction that it
disrupts the functional Smad3-Smad4 complex [34].
Crystallographic and calorimetric data indicate that the
Tang and Zhang Cell & Bioscience 2011, 1:43
http://www.cellandbioscience.com/content/1/1/43
Page 3 of 5transcriptionally active Smad complexes are heteromeric
trimers comprising one Smad4 and two phosphorylated
R-Smads. The interface between these Smad moieties is
formed between the C-terminal tail and the L3-loop of
the MH2 domain [29]. The ubiquitin attachment site of
Smad4 ubiquitination in Moustakas’ study was deter-
mined to be K507 by mass spectrometry [20]. However,
mutational studies by Piccolo’s group showed that the
most important recipient lysine for mono-ubiquitination
is the neighboring K519 [34] (Figure 1). Given the close
proximity of either of these two lysines to the actual
contacting residues in the MH2 domain, it is difficult to
conceive that a bulky mono-ubiquitin chain could
enhance the heteromeric bounding within the Smad
complexes; nevertheless, Itch poly-ubiquitination of
Smad2 has been shown to promote the interaction
between Smad2 and TbRI as discussed above [19]. Not-
withstanding the functional discrepancy between these
two studies, one thing is clear that Smad4 can be modi-
fied either by poly-ubiquitin chains or by mono-ubiqui-
tin. These two forms of modification have differential
impact on Smad4 function.
The potential influence of mono-ubiquitin modifica-
tion on Smad4 function suggests that it is likely regu-
lated to afford additional control of TGF-b signaling.
Indeed, in a siRNA-based nonbiased screen for novel
TGF-b signaling modulators among 75 known or pre-
dicted DUBs, FAM/USP9x was identified, and an antag-
onizing E3 ligase, Ectodermin (Ecto)/Tif1g was also
identified through candidate gene approach [34] (Figure
2). Comparative experiments in Drosophila, zebrafish,
and mammalian cells showed that this pair of counter-
acting E3 and DUB are functionally conserved, under-
scoring the evolutionary importance of Smad4 mono-
ubiquitin modification.
Concluding remark and perspective
In contrast to an abrupt “turning-off” role of the degra-
dative ubiquitination, the non-degradative ubiquitination
exerts versatile regulation of TGF-b signaling through
various mechanisms. It can be a positive regulation by
promoting the receptor-mediated phosphorylation of
Smad2 or a negative regulation by disrupting Smad
complex formation. Despite the remarkable recent pro-
gress in this highly active area of research, many ques-
tions remain. For example, what is the temporal order
for ubiquitins to modify Smad proteins in response to
TGF-b, and what is structural basis for poly-ubiquitin
chains to enhance Smad complex formation? It is also
unclear what makes Smad2 such a poor substrate for
Smurf2-mediated ubiquitination, although sharing a
high degree of sequence identity with Smad3 and is cap-
able of binding to Smurf2? Finally, what determines the
specificity of Itch and Smurf2, the two related HECT-
domain E3 ligases, in selecting different substrates to
regulate TGF-b signaling? Rigorously addressing these
questions will be challenging, but the final outcome will
undoubtly provide further insight into how TGF-b sig-
naling is regulated.
The poly- and oligo-ubiquitin chains discussed in this
review are all form via the K48 linkage. Other internal
lysine residues, such as K63, could also be utilized to
support the addition of homogenic or heterogenic chain
linkage for the ubiquitin modification of various path-
way components, raising the possibility that TGF-b sig-
naling can be regulated by yet other forms of ubiquitin
modification. High-resolution systematic mass spectro-
metry analysis coupled with efficient ubiquitin affinity
purification will prove to be instrumental in this emer-
ging area of research.
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